两性霉素B脂质体的药学特点和临床应用  

Pharmaceutical characteristics and clinical applications of liposomal amphotericin B

作　　者：孔旭东[1] 李少强 陈玥 李朋梅[1] KONG Xu-dong;LI Shao-qiang;CHEN Yue;LI Peng-mei(Department of Pharmacy,China-Japan Friendship Hospital,Beijing 100029,China)

机构地区：[1]中日友好医院药学部,北京100029

出　　处：《临床药物治疗杂志》2023年第11期6-11,共6页Clinical Medication Journal

摘　　要：两性霉素B是广谱、强效的抗真菌药物,特别是在针对免疫功能低下人群的侵袭性真菌病、耐药真菌及少见真菌感染的治疗中有不可替代的地位。其中,两性霉素B脂质体(liposomal amphotericin B,商品名:AmBisome)在两性霉素B制剂中疗效、安全性和便捷性等方面都有突出优势,因此在国际指南中推荐级别也高于其他两性霉素B制剂。2023年2月,国家药品监督管理局批准两性霉素B脂质体上市,但临床对两性霉素B脂质体的特点及与其他制剂的差异缺乏系统性认识。本文对两性霉素B脂质体的药学特点、指南推荐情况及临床应用等进行综述,旨在为其临床合理使用提供参考。Liposomal amphotericin B is a broad-spectrum and potent antifungal drug,particularly invaluable in the treatment of invasive fungal diseases in immunocompromised populations,as well as in the management of drug-resistant and rare fungal infections.Among various amphotericin B formulations,liposomal amphotericin B(trade name:AmBisome)stands out due to its superior efficacy,safety,and convenience.Consequently,international guidelines recommend liposomal amphotericin B over other amphotericin B formulations.In February 2023,liposomal amphotericin B was approved by National Medical Prodllcts Adminstration.However,there is a lack of systematic understanding regarding the specific characteristics of liposomal amphotericin B and its differences from other formulations in clinical practice.This article reviews the pharmaceutical characteristics,guideline recommendations,and clinical applications of liposomal amphotericin B,aiming to provide guidance for it's rational clinical use.

关 键 词：两性霉素B脂质体 两性霉素B 侵袭性真菌病 抗真菌药物 

分 类 号：R978.5[医药卫生—药品]